Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial

Fig. 1

Study design. Arm A: Deferred CN followed by nivolumab or TKI-IO therapy. Arm B: No surgery, nivolumab or TKI-IO therapy. Arm C: Patients not eligible for randomization into Arm A or B. CN: Cytoreductive Nephrectomy; IO: Immunotherapy; mRCC: metastatic Renal Cell Carcinoma; Nivo: Nivolumab; TKI: Tyrosine Kinase Inhibitor. Generated with BioRender.com

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us